| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia, JY Han, J Molina, ... The Lancet 387 (10027), 1540-1550, 2016 | 6603 | 2016 |
| Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, ... JAMA oncology 4 (5), e180013-e180013, 2018 | 1627 | 2018 |
| First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised … YY Janjigian, K Shitara, M Moehler, M Garrido, P Salman, L Shen, ... The Lancet 398 (10294), 27-40, 2021 | 1569 | 2021 |
| Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial RS Finn, BY Ryoo, P Merle, M Kudo, M Bouattour, HY Lim, V Breder, ... Journal of Clinical Oncology 38 (3), 193-202, 2020 | 1436 | 2020 |
| Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 … K Shitara, E Van Cutsem, YJ Bang, C Fuchs, L Wyrwicz, KW Lee, ... JAMA oncology 6 (10), 1571-1580, 2020 | 786 | 2020 |
| LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal … M Moehler, K Shitara, M Garrido, P Salman, L Shen, L Wyrwicz, ... Annals of Oncology 31, S1191, 2020 | 250 | 2020 |
| Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the … YJ Bang, YK Kang, DV Catenacci, K Muro, CS Fuchs, R Geva, H Hara, ... Gastric Cancer 22, 828-837, 2019 | 234 | 2019 |
| Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer K Shitara, JA Ajani, M Moehler, M Garrido, C Gallardo, L Shen, ... Nature 603 (7903), 942-948, 2022 | 217 | 2022 |
| Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). RS Finn, BY Ryoo, P Merle, M Kudo, M Bouattour, HY Lim, VV Breder, ... Journal of Clinical Oncology 37 (15_suppl), 4004-4004, 2019 | 211 | 2019 |
| KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. CS Fuchs, T Doi, RWJ Jang, K Muro, T Satoh, M Machado, W Sun, ... Journal of Clinical Oncology 35 (15_suppl), 4003-4003, 2017 | 204 | 2017 |
| Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. J Tabernero, E Van Cutsem, YJ Bang, CS Fuchs, L Wyrwicz, KW Lee, ... Journal of Clinical Oncology 37 (18_suppl), LBA4007-LBA4007, 2019 | 190 | 2019 |
| Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial M Szarek, HD White, GG Schwartz, M Alings, DL Bhatt, VA Bittner, ... Journal of the American College of Cardiology 73 (4), 387-396, 2019 | 190 | 2019 |
| KEYNOTE-240 investigators. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial RS Finn, BY Ryoo, P Merle, M Kudo, M Bouattour, HY Lim, V Breder, ... J Clin Oncol 38 (3), 193-202, 2020 | 187 | 2020 |
| Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective … A Carmona-Bayonas, P Jiménez-Fonseca, J Virizuela Echaburu, ... Journal of Clinical Oncology 33 (5), 465-471, 2015 | 178 | 2015 |
| Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy I Riquelme, K Saavedra, JA Espinoza, H Weber, P García, B Nervi, ... Oncotarget 6 (28), 24750, 2015 | 157 | 2015 |
| Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial RS Herbst, P Baas, JL Perez-Gracia, E Felip, DW Kim, JY Han, JR Molina, ... Annals of Oncology 30 (2), 281-289, 2019 | 102 | 2019 |
| Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry P Jiménez Fonseca, A Carmona-Bayonas, R Hernández, A Custodio, ... British journal of cancer 117 (6), 775-782, 2017 | 92 | 2017 |
| Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells R Erices, ML Bravo, P Gonzalez, B Oliva, D Racordon, M Garrido, ... Reproductive sciences 20 (12), 1433-1446, 2013 | 92 | 2013 |
| Diagnosis of mild platelet function disorders. Reliability and usefulness of light transmission platelet aggregation and serotonin secretion assays T Quiroga, M Goycoolea, V Matus, P Zuniga, C Martinez, M Garrido, ... British journal of haematology 147 (5), 729-736, 2009 | 66 | 2009 |
| Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer M Garrido, A O'Brien, S González, JM Clavero, E Orellana Chest 132 (6), 1997-1999, 2007 | 63 | 2007 |
